Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?

Executive Summary

Following Sandoz’s Zarxio playbook, Pfizer plans to market Inflectra while patent litigation continues; February 2017 trial on cell culture media patent could answer question of potential damages.

Advertisement

Related Content

Interview: Celltrion's Journey To The Top
Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Pfizer Will Support Inflectra Launch With Dedicated Sales Force
Trump Victory To Breathe Life Into Korean Biopharmas?
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Pfizer Eliminates Roadblock To Remicade Biosimilar Launch
Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel